Sinopharm inactivated COVID-19 vaccines could be available by the end of 2020
Two new inactivated COVID-19 vaccines developed by Sinopharm(CNPGC) were unveiled for the first time at the 2020 China International Fair for Trade in Services, which opened in Beijing last weekend.

Photo by Beijing Daily
The vaccines could reach the market by year's end
These two inactivated COVID-19 vaccines exhibited by Sinopharm are now both in the final phase III clinical trials and are being tested in the UAE, Bahrain, Peru, Morocco, Argentina and other countries and regions. 50,000 people have been vaccinated and the sample population has now covered 115 countries, leading the world in all aspects of progress.
The company’s facilities in Beijing and Wuhan have enough capacity to make more than 300 million doses a year.

Photo by chinatimes
“The inactivated vaccine won’t be priced too high”
“The inactivated vaccine won’t be priced too high,” Sinopharm Chairman Liu Jingzhen told state media in China. Liu Jingzhen said it’s expected to cost a couple hundred yuan for one shot, and it would be less than 1,000 yuan ($145) for two doses.
Liu Jingzhen also revealed that he has been vaccinated, "I got two shots of the inactivated COVID-19 vaccine and had no adverse reactions yet."
Zheng Zhongwei, of China's National Health Commission said in media on CCTV that the pricing of the vaccine depends only on the cost. "What's certain is that the pricing must be lower than what Liu Jingzhen said."
Zheng noted that for the next step of preventing a possible outbreak this autumn and winter, vaccines' availability will be extended to people working in food markets, transport systems and services industries.
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Vaccines - COVID-19 epidemic drives rapid industry development
-
Which Is The Best Covid Vaccine In The World
-
Which Companies Are Making Covid Vaccines
-
The Indian Variant Vaccine Efficacy is only 10%, and it was abandoned by South Africa
-
Compensation Methods For Adverse Reactions To Vaccines In The Post-Epidemic Period
-
The Johnson & Johnson Vaccine Is Only 72% Effective, Is It An Inferior Vaccine?
-
Research On The Distribution Of The Incubation Period Of COVID-19
-
How Many Covid Vaccines Are Made Per Second?
-
Protein Based Vaccines Examples : The Second Generation Of The COVID-19 Vaccine Is Coming
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
Recommend Reading
-
U.S. 10% Temporary Tariff Expires, New Section 301 Tariffs Not Yet Implemented
-
Global Trade Data for Epoxy Resin in 2025 Released: Asia Accounted for $640 Million in Imports, Vietnam Emerges as Top Buyer
-
U.S. Strikes Three Iranian Tankers as “Tanker-for-Tanker” Escalation Raises Chemical Shipping Risk
-
Explosions Reported Near Saudi Aramco Headquarters as Missile Is Intercepted Over Dhahran
-
Panama Canal Delays Deeper Draft Cut, but Transit Capacity Is Still Tightening
-
Polyethylene Strengthens, May See High-Level Fluctuations in the Future
-
Business Society October 14, 2026 PVC Trend Analysis: Market Bias Toward the Bearish Side
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
Business Society October 14, 2026 Acrylonitrile Trend Analysis: Clear Uptrend
-
Business Society October 14, 2026 HDPE Trend Analysis: Strong Consolidation